Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive
MT Newswires Live
Jul 27
Nyrada (ASX:NYR) ended the June quarter with a cash balance of about AU$8.4 million, up from AU$6.7 million as of March 31, according to a Monday filing with the Australian bourse.
Cash operating outflows for the June quarter totaled about AU$1.7 million, offset by AU$60,000 of interest income and the receipt of a roughly AU$2.5 million research and development tax incentive from the Australian government, per the filing.
The company said its phase 2a clinical trial of Xolatryp in heart attack patients remains on track for completion next year, with the final patient expected to be dosed in mid-2027.
Nyrada shares fell 1% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.